[Preliminary clinical studies on the antiparkinson effects of 17-monochloroacetylajmaline].
D000404:Ajmaline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001919:Bradycardia / Q000139:chemically induced; D002713:Chlorine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D006801:Humans; D009127:Muscle Rigidity / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D013272:Stomach Diseases / Q000139:chemically induced; D014202:Tremor / Q000188:drug therapy
D000978:Antiparkinson Agents; D000404:Ajmaline; D002713:Chlorine
Osservazioni cliniche preliminari sugli effetti antiparkinsoniani della 17-monocloroacetilajmalina